Worldwide, iron deficiency anemia (IDA) is the most common nutritional deficiency,
and its management remains a challenge in many cases.(OIT)Oral iron therapy, in appropriate
doses and for a sufficient duration, is an effective first-line strategy
for most patients.
But some patients do not experiencean optimal response to(OIT).The need is still
current and clinically relevant for predictors of response to OIT. Hepcidin-25, a major regulator
of iron metabolism, may be use as a reliable guide for the use of iron and be one of
them.112 patientswith IDA were enrolled in this follow up clinical trial, Selected from two
university, hospitals in Damascus between JUNE2015 and JUNE2016. For patients who
met the inclusion criteria, Baseline CBC, iron studies, and serum hepcidin-25 were measured,
and then they received a 14-day course of oral iron (ferrous gluconate 325mg/ 3 times
daily). Patients who achieved <1g/dl increase in Hb in 14 days were categorized as “nonresponders”.
Screening hepcidin levels were (40.18± 86.35) versus (6.37±10.37)(p=
0.041(innonresponders versus responders to oral iron trial. HepcidinCutoff of >14.3 ng/ml,
showed sensitivity of 40%,specificity of 90.2%, andpositive predictive value of 60% andnegative
predictive value of 80% for predicting nonresponsiveness to oral iron.We conclude
that serum hepcidin25predicts poorly nonresponsivenesstooral iron therapy in IDA
patients, but it is superior to ferritin and TSAT for this purpose.
Hepcidin-25 is a peptide hormone plays an important role in
regulating the systematic iron homeostasis. This paper was
conducted to study the correlations of Hepcidin with some iron
status markers and red cell indices among patients with iron
def
iciency anemia (IDA) and healthy controls in Damascus. Our
study comprised 20 IDA patients (Hb≤11 g/dl for men and
women,Tsat≤20% and ferritin <30 ng/dl) and 10 healthy non
IDA controls. Complete hemogram was performed, iron status
markers (serum iron, total iron binding capacity and ferritin)
were measured and transferrin saturation was calculated .
This study is conducted to assess the role of hepcidin as a biomarker of iron status in haemodialysis patients. The study included88 patients who had end-stage renal disease ( ESRD), and were treated with haemodialysis in the Department of Renal Medi
cine in Al-Assad University Hospital in Lattakia.
Serum hepcidin and ferritinlevelswere measured, and transferrin saturation (TSAT) was calculated after measuringthe total iron binding capacity (TIBC), these markers were then attached with iron and compared to know the hardest correlation.
Results show that all the patients had high serum hepcidin levels,there was a statistically significant relation between iron and hepcidin, where P-VALUE smaller than 0.05, this relationship was inversal, hardly 40% the stongest correlation.
Conclusion:
These findings suggest that the increased hepcidinin haemodialysis patients may contribute to abnormal ironregulation and erythropoiesis, and may be a novel biomarker of iron status and erythropoietin resistance.
